Milenko Cicmil is listed as an executive officer and director on 2 SEC Form D filings by 1 issuer between Nov 2024 and Dec 2025: Tasca Therapeutics Corp (Cambridge, MA — biotechnology — 2024–2025; $48.1M reported sold to 9 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside David Fallace (2 shared filings), Drew King (2 shared filings), Michael Aberman (2 shared filings), Praveen Tipirneni (2 shared filings), Xu Wu (2 shared filings) and 1 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Milenko. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Milenko Cicmil and found 2 differences: Form D filed 16 days after the first sale; Address moved from Boston, MA to Cambridge, MA.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.